Prescription Drug User Fee Act (PDUFA, 1992)
artifactBiotech & Transhumanism
The agency that approves your medicines now gets nearly half its budget from the drug companies it's supposed to police.
Who they are
The Prescription Drug User Fee Act (PDUFA, 1992), which lets the FDA collect fees directly from drug and biotech companies.
What they do
It turned company payments from a supplemental funding source into a fundamental structural dependency for the FDA.
How it works
Reauthorized every 5 years (PDUFA VII runs through FY2027), by FY2022 industry user fees were about 46% of the FDA's total operating budget ($2.9B) and ~66% of its human-drugs program budget ($1.4B), with the FY2025 application fee at $4,310,002.
Why it matters
The desc's point is blunt: the regulator is now structurally dependent on the very industry it regulates.
The engine's record — word for word
Authorized FDA to collect user fees directly from pharmaceutical + biotech companies to fund the drug review process. Began as supplemental funding mechanism; evolved into fundamental structural dependency. Reauthorized every 5 years (PDUFA VII extends program through FY2027). **By FY2022:** industry user fees = ~46% of FDA total operating budget ($2.9B); ~66% of human drugs program budget ($1.4B). FY2025 application-with-clinical-data fee = $4,310,002. The regulator is structurally dependent on the entity it regulates.
Follow the trail
Walk this on the live map →